Lipocine (NASDAQ:LPCN) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN – Free Report) to a hold rating in a report issued on Saturday,Wall Street Zen reports.

Several other analysts have also recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Lipocine in a research note on Tuesday, September 22nd. HC Wainwright reissued a “neutral” rating and issued a $4.00 target price on shares of Lipocine in a research note on Monday, September 21st. Finally, Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, November 13th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $4.00.

Get Our Latest Report on LPCN

Lipocine Stock Performance

NASDAQ LPCN opened at $1.48 on Friday. The business has a fifty day moving average price of $1.78 and a 200 day moving average price of $3.36. Lipocine has a one year low of $1.36 and a one year high of $12.37. The company has a market cap of $16.38 million, a P/E ratio of -1.16 and a beta of 0.49.

Lipocine (NASDAQ:LPCN – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.31. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 46.52% and a negative net margin of 249.23%. As a group, sell-side analysts predict that Lipocine will post -1.54 EPS for the current fiscal year.

Insider Activity

In other news, Director John Higuchi acquired 75,000 shares of the company’s stock in a transaction that occurred on Thursday, November 19th. The stock was purchased at an average price of $1.51 per share, with a total value of $113,250.00. Following the completion of the acquisition, the director owned 316,365 shares of the company’s stock, valued at $477,711.15. This trade represents a 31.07% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have bought a total of 112,568 shares of company stock valued at $195,424 over the last ninety days. Corporate insiders own 4.69% of the company’s stock.

Institutional Investors Weigh In On Lipocine

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Seven Fleet Capital Management LP purchased a new position in shares of Lipocine during the 1st quarter worth approximately $998,000. Stempoint Capital LP acquired a new position in Lipocine during the first quarter worth $1,282,000. ADAR1 Capital Management LLC purchased a new position in shares of Lipocine during the first quarter worth $185,000. Eversept Partners LP purchased a new position in shares of Lipocine during the first quarter worth $2,357,000. Finally, Exome Asset Management LLC acquired a new stake in shares of Lipocine in the first quarter valued at $486,000. 9.11% of the stock is owned by hedge funds and other institutional investors.

About Lipocine

(Get Free Report)

Lipocine Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral treatments for health conditions with significant unmet medical needs. Its proprietary drug-delivery technology is designed to enable medicines that may otherwise require different formulations or routes of administration to be taken orally. The company’s lead commercial-stage product is Tlando, an oral testosterone-replacement therapy approved in the United States for adult men with testosterone deficiency.

Further Reading

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.